×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NBIX – neurocrine biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NBIX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
04:10 am
nbix
Congenital Adrenal Hyperplasia Landscape Research 2024: Comprehensive Insights About 8+ Pipeline Drugs Featuring Neurocrine Biosciences, Spruce Biosciences, Lundbeck, and HBM Alpha Therapeutics [Yahoo! Finance]
Low
Report
Congenital Adrenal Hyperplasia Landscape Research 2024: Comprehensive Insights About 8+ Pipeline Drugs Featuring Neurocrine Biosciences, Spruce Biosciences, Lundbeck, and HBM Alpha Therapeutics [Yahoo! Finance]
11/11
02:01 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/8
08:19 am
nbix
Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality [Yahoo! Finance]
Low
Report
Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality [Yahoo! Finance]
11/7
08:30 am
nbix
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
Low
Report
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
11/5
04:01 pm
nbix
Neurocrine Biosciences to Participate at Investor Conferences in November
Medium
Report
Neurocrine Biosciences to Participate at Investor Conferences in November
11/4
08:42 am
nbix
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia [Yahoo! Finance]
Medium
Report
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia [Yahoo! Finance]
11/4
08:30 am
nbix
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
Medium
Report
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
11/4
08:25 am
nbix
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
Medium
Report
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2024
07:00 am
NBIX
neurocrine biosciences, inc.
BEAT
Report
3.6%
neurocrine biosciences, inc.
8/1/2024
07:00 am
NBIX
neurocrine biosciences, inc.
BEAT
Report
6.0%
neurocrine biosciences, inc.
5/1/2024
07:00 am
NBIX
neurocrine biosciences, inc.
BEAT
Report
0.7%
neurocrine biosciences, inc.
2/7/2024
07:00 am
NBIX
neurocrine biosciences, inc.
BEAT
Report
-6.1%
neurocrine biosciences, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
05:59 pm
nbix
Form 4 NEUROCRINE BIOSCIENCES For: Nov 08 Filed by: ROBERTS EIRY
Low
Report
Form 4 NEUROCRINE BIOSCIENCES For: Nov 08 Filed by: ROBERTS EIRY
11/7
07:43 pm
nbix
Form 4 NEUROCRINE BIOSCIENCES For: Nov 04 Filed by: SHERWIN STEPHEN A
Medium
Report
Form 4 NEUROCRINE BIOSCIENCES For: Nov 04 Filed by: SHERWIN STEPHEN A
11/1
07:52 pm
nbix
Form 4 NEUROCRINE BIOSCIENCES For: Nov 01 Filed by: Gano Kyle
Low
Report
Form 4 NEUROCRINE BIOSCIENCES For: Nov 01 Filed by: Gano Kyle
11/1
08:32 am
nbix
Form 8-K NEUROCRINE BIOSCIENCES For: Oct 31
Low
Report
Form 8-K NEUROCRINE BIOSCIENCES For: Oct 31
10/30
07:05 am
nbix
Form 10-Q NEUROCRINE BIOSCIENCES For: Sep 30
Medium
Report
Form 10-Q NEUROCRINE BIOSCIENCES For: Sep 30
10/30
07:03 am
nbix
Form 8-K NEUROCRINE BIOSCIENCES For: Oct 30
Medium
Report
Form 8-K NEUROCRINE BIOSCIENCES For: Oct 30
10/17
09:54 am
nbix
Form SC 13G NEUROCRINE BIOSCIENCES Filed by: STATE STREET CORP
Low
Report
Form SC 13G NEUROCRINE BIOSCIENCES Filed by: STATE STREET CORP
10/11
04:02 pm
nbix
Form 8-K NEUROCRINE BIOSCIENCES For: Oct 11
Low
Report
Form 8-K NEUROCRINE BIOSCIENCES For: Oct 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/29
Q2/2019 6/30/2019 EPS 0.540 ZacksConsensus 0.270 ActVsEst 0.270 - Beat
10.3%
11/8 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.4%
5/29 Form 4 NEUROCRINE BIOSCIENCES For: May 24 Filed by: Bozigian Haig P. 5.2%
3/25 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.6%
4/17 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.9%
8/8 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.6%
10/16 Form 4 NEUROCRINE BIOSCIENCES For: Oct 14 Filed by: Lloyd-Smith Malcolm 3.3%
7/8 Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results 3.2%
5/7 Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019 3.0%
1/28 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 3.0%
11/8 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.4%
5/29 Form 4 NEUROCRINE BIOSCIENCES For: May 24 Filed by: Bozigian Haig P. 5.2%
3/25 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.6%
4/17 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.9%
8/8 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.6%
10/16 Form 4 NEUROCRINE BIOSCIENCES For: Oct 14 Filed by: Lloyd-Smith Malcolm 3.3%
7/8 Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results 3.2%
5/7 Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019 3.0%
1/28 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 3.0%
TOP News Decliners
1/10
Form 4 NEUROCRINE BIOSCIENCES For: Jan 08 Filed by: ROBERTS EIRY
-8.1%
7/31 Form 4 NEUROCRINE BIOSCIENCES For: Jul 30 Filed by: Bozigian Haig P. -4.5%
4/30 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at William Blair. -3.8%
2/24 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at William Blair. They set an "outperform" rating on the stock. -3.8%
6/4 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock. -3.7%
5/17 Form 3 NEUROCRINE BIOSCIENCES For: May 07 Filed by: Cooke Julie -3.3%
4/30 Form 4 NEUROCRINE BIOSCIENCES For: Apr 28 Filed by: ABERNETHY MATT -3.3%
4/27 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. -3.0%
2/4 Q4/2019 12/31/2019 EPS 1.050 ZacksConsensus 0.820 ActVsEst 0.230 - Beat -2.9%
8/8 Form 4 NEUROCRINE BIOSCIENCES For: Aug 06 Filed by: GORMAN KEVIN CHARLES -2.4%
7/31 Form 4 NEUROCRINE BIOSCIENCES For: Jul 30 Filed by: Bozigian Haig P. -4.5%
4/30 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at William Blair. -3.8%
2/24 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at William Blair. They set an "outperform" rating on the stock. -3.8%
6/4 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock. -3.7%
5/17 Form 3 NEUROCRINE BIOSCIENCES For: May 07 Filed by: Cooke Julie -3.3%
4/30 Form 4 NEUROCRINE BIOSCIENCES For: Apr 28 Filed by: ABERNETHY MATT -3.3%
4/27 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. -3.0%
2/4 Q4/2019 12/31/2019 EPS 1.050 ZacksConsensus 0.820 ActVsEst 0.230 - Beat -2.9%
8/8 Form 4 NEUROCRINE BIOSCIENCES For: Aug 06 Filed by: GORMAN KEVIN CHARLES -2.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: